KONEXElectrical Equipment332190

OceansBio

₩2,600▲ 3.38%2026-10-02 close

Market Cap

₩3.8B

Turnover

₩259,590

Volume

103 shares

Shares out.

1.5M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Epilepsy Electroceutical Pioneer: Regulatory Approval and Monetization Are the Critical Tests

OceansBio is Korea's sole epilepsy electroceutical startup with a differentiated AI-driven wireless-charging device, yet revenue remains negligible and meaningful uncertainty surrounds the path to global regulatory approvals.

1
Listed on KONEX in January 2025 via Kyobo Securities as designated advisor, with a publicly stated plan to transfer-list on KOSDAQ
2
Korea's only epilepsy electroceutical developer, holding two pipeline products: a non-invasive transauricular VNS (TaVNS) and a near-complete implantable VNS (iVNS)
3
Rechargeable (secondary battery) wireless charging plus AI-driven stimulation control eliminates repeat surgeries and extends device life beyond 10 years versus industry-standard primary-battery devices
4
FY2023 revenue KRW 126 million (+33% YoY) with ongoing operating losses, reflecting a pre-commercialization R&D stage where meaningful sales are expected only post-approval
5
The global electroceuticals market was valued at approximately USD 22.8 billion in 2024 and is projected to grow at a CAGR of roughly 6–8% to over USD 42 billion by 2034

Business structure

OceansBio is a bio-medical device startup specializing in electroceuticals—devices that harness electrical signals in the brain and nervous system to treat disease.

Its core pipeline encompasses two products: TaVNS (transauricular vagus nerve stimulation), a non-invasive device applying gentle electrical impulses to the vagus nerve via the ear, and iVNS, an implantable vagus nerve stimulator targeting epilepsy and depression that is reportedly in its final development stage.

The company's key technical differentiation lies in AI-based circuit design optimization and a rechargeable (secondary battery) wireless charging system; while most commercially available electroceuticals use primary batteries requiring surgery costing approximately KRW 50 million upon depletion every 3–5 years, OceansBio's device enables wireless recharging via smartphone app and is designed for more than 10 years of safe in-body use.

The device is miniaturized to approximately 4 cm × 6 cm × 5 mm, and its embedded AI learns epileptic precursors to activate pulses only when needed, extending battery life while personalizing therapy. A companion smartphone app and remote monitoring platform are also under development.

Future indication expansion from epilepsy and depression toward Alzheimer's disease and metabolic disorders is planned, with primary target markets being U.S. and European hospitals and academic medical centers.

The company employs approximately 17 people under a founder-led structure, with CEO Lee Hyeon-woong holding a 78.98% stake.

In Korea, competitors such as Wibrain and Neuroaid focus on non-invasive electroceuticals for other indications, leaving OceansBio as the sole domestic developer of an implantable epilepsy electroceutical, while globally, large medtech incumbents such as LivaNova, Abbott, and Medtronic already dominate the established VNS market.

Recent trends

OceansBio formally listed on the Korea Exchange KONEX market on January 14, 2025—approximately six years after its founding in 2018—with Kyobo Securities serving as its designated listing advisor.

The most recent publicly available financial data shows FY2023 annual revenue of KRW 126 million, representing 33% YoY growth, though the absolute scale remains very small and the company continues to post operating losses consistent with a pre-commercialization R&D stage.

As of June 7, 2026, the stock closed at KRW 3,625, down 14.81% on the day, with market capitalization in the tens of billions of KRW range—an extreme micro-cap.

The 52-week high was previously reported at KRW 5,810, placing the current price significantly below the peak, while the 52-week low of KRW 2,295 indicates the stock has recovered modestly from its trough. Daily trading value is negligible, reflecting the characteristically thin liquidity of the KONEX market.

On the funding side, the company raised approximately KRW 1.5 billion across seed and pre-Series A rounds from investors including Seriesventes, The Ventures, Korea Credit Guarantee Fund, SNU Holdings, PNU Holdings, D.CAMP, and KVIC.

In 2021, it was simultaneously selected for the government's TIPS (Technology Innovation Program for Startups) and First Penguin programs. Through the Gyeongnam-type accelerating support project, it established a U.S. Manhattan branch office, laying early groundwork for global market entry.

More recently, the company signed an MOU with CoresTech for AI-speaker-based care services, extending its collaboration footprint.

Outlook

OceansBio's publicly stated mid-term targets include a KOSDAQ transfer listing in 2026 and revenues of KRW 12.5 billion by 2027. Achieving these milestones requires successful clinical results and MFDS (Korea) approval for the near-complete iVNS implantable device, along with U.S.

FDA clinical trial authorization and European CE mark certification. The global electroceuticals market, valued at approximately USD 22.8 billion in 2024 and growing at an estimated CAGR of 6–8%, provides a structurally favorable backdrop.

The convergence of AI and wireless technologies is broadening demand for both non-invasive and implantable devices simultaneously, making OceansBio's dual-pipeline approach (TaVNS + iVNS) directionally aligned with market trends.

However, medical device startups typically require 10–20 years from inception to commercial launch, and Class III or higher implantable devices face particularly stringent regulatory requirements, elevating timeline risk.

Funding continuity is another key variable; the company has reportedly navigated near-crisis funding shortfalls during periods of tightened VC sentiment in the healthcare sector. The outcome of its KOSDAQ transfer bid will depend heavily on the pace of clinical progress and the visibility of a credible revenue ramp.

Bull factors

Sole Domestic Player in Epilepsy Electroceuticals

OceansBio is the only Korean company developing an implantable electroceutical specifically for epilepsy, while domestic rivals focus on non-invasive devices for ADHD, depression, or migraine.

This unique positioning creates a first-mover advantage in domestic regulatory filings and hospital supply agreements once approval is secured. The company's dual-pipeline structure (implantable + non-invasive) further distinguishes it. Its niche dominance also makes it an attractive potential M&A target for a larger global medtech player.

Structural Differentiation via Secondary Battery and AI Technology

OceansBio's wireless-charging secondary-battery platform structurally eliminates the costly re-surgery (approximately KRW 50 million per procedure) required by competing primary-battery devices when they deplete.

Its AI-driven precursor detection and personalized stimulation control simultaneously extend battery life and improve therapeutic efficacy. AI-based shape optimization maintains device miniaturization despite the addition of wireless charging functionality, preserving implant convenience.

Collectively, these technologies offer a meaningfully superior patient experience compared to established global competitor products.

Structural Growth of the Global Electroceuticals Market

According to market research firms, the global electroceuticals market is projected to expand from approximately USD 22.8 billion in 2024 to over USD 42 billion by 2034 at a CAGR of roughly 6.6–7.9%.

Core growth drivers include an aging global population, rising prevalence of chronic neurological and cardiovascular conditions, and expanding demand for non-pharmacological treatments among drug-resistant patients.

Epilepsy in particular shows rising incidence in older demographics, structurally broadening the addressable market. The absence of dominant oligopolistic incumbents—unlike the traditional pharmaceutical sector—makes the electroceuticals space relatively accessible to innovative technology-driven startups.

Bear factors

Negligible Revenue and Persistent Losses at an Early Stage

Annual revenue of approximately KRW 126 million in FY2023 is negligible, and the nature of an implantable medical device means that meaningful revenue generation will be delayed until domestic and international regulatory approvals are secured.

Total external funding raised to date of roughly KRW 1.5 billion is modest relative to the capital requirements for clinical trials, regulatory filing, and global market entry.

The company reportedly navigated multiple near-cash-shortfall crises during periods of reduced VC appetite for healthcare startups, raising concerns about funding continuity. A credible timeline and path to breakeven have yet to be publicly articulated.

Regulatory Risk: High Barriers for Class III Implantable Medical Devices

The iVNS implantable electroceutical is classified as a Class III or higher medical device in both Korea and major international markets, requiring rigorous clinical studies and regulatory filings. While U.S.

FDA clinical trial authorization and CE certification are stated goals, the design, patient recruitment, and safety data collection for an implantable neurostimulator typically take years and substantial capital.

Industry convention places the full cycle from inception through clinical approval and reimbursement listing at 10–20 years for medical device startups, constraining near-term performance expectations. Clinical failures or safety events could reset the entire development timeline.

KONEX Micro-Cap Liquidity Risk and Ownership Concentration

The KONEX market is structurally illiquid, and OceansBio's daily trading value as of June 7, 2026, was effectively just a few thousand KRW—an extreme illiquidity reading. With CEO Lee Hyeon-woong owning 78.98% of outstanding shares, minority shareholder protection and secondary float supply are structurally weak.

A market capitalization in the low tens of billions of KRW makes meaningful institutional participation essentially impossible and amplifies price volatility. If the KOSDAQ transfer listing does not materialize, investors face very limited options for liquidity exit.

Risk factors

Healthcare VC Funding Contraction Risk

A sustained contraction in global healthcare VC sentiment would impair OceansBio's ability to raise the capital needed for clinical trials and commercialization. The company has already experienced multiple near-cash-shortfall crises and is reportedly pursuing new VC funding for business expansion.

The success of this fundraise is tightly linked to its KOSDAQ transfer listing timeline. Interest rate conditions and shifts in sector risk appetite represent the most consequential external macro variables for this early-stage company.

Technology and Capital Gap Versus Global Medtech Incumbents

The global VNS market is already populated by well-capitalized incumbents such as LivaNova, Abbott, and Medtronic, each with extensive clinical datasets and established hospital relationships. Bridging the technology and clinical-evidence gap with these players in a short time frame is a formidable challenge.

OceansBio's wireless charging and AI differentiation can translate into a real competitive edge only after large-scale clinical validation and the building of prescriber trust among physicians and hospital systems.

Scenarios in which larger players internalize similar technologies or preemptively acquire competing startups cannot be excluded.

Regulatory Approval and Reimbursement Coverage Risk

Even after obtaining regulatory approvals domestically and internationally, reimbursement coverage will ultimately determine actual market access. Without health insurance listing, patients bear the full device cost, potentially reducing prescription demand sharply. Foreign certifications (U.S.

FDA, European CE) are substantially more demanding than domestic Korean processes, and country-specific regulatory requirements vary widely, increasing the probability that global launch timelines will slip relative to stated plans.

The approximately five-year commercial product lifecycle in medical devices means that delayed approvals directly erode competitive positioning upon eventual market entry.

Overall view

OceansBio holds two constructive attributes: a uniquely differentiated AI and wireless-charging electroceutical platform, and exposure to a structurally growing global market where no dominant oligopoly yet exists.

Its January 2025 KONEX listing marks a meaningful milestone as the company's first access to formal capital markets. However, with FY2023 revenues of just KRW 126 million, the company remains in a very early commercial stage, and the regulatory path for a Class III implantable device is long and uncertain.

Concentrated founder ownership, extreme KONEX illiquidity, and funding continuity risk represent significant structural constraints from an investment standpoint.

The most important near-term catalysts to monitor are the outcome of any KOSDAQ transfer listing bid in 2026 and clinical progress milestones for iVNS alongside FDA or CE authorization announcements.

At this stage, a cautious stance is warranted: while the technology potential is real, the commercialization timeline, regulatory execution risk, and market structure limitations require careful ongoing assessment.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 12 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.